Pathology & Your Report: The Data that Defines Your Disease

A pathology report is an important component of your diagnostic record, but it can be notoriously difficult to read. For atypical Chronic Myeloid Leukemia (aCML), the diagnosis is an integrated clinical, morphologic, cytogenetic, molecular, and exclusion-based assessment. The final classification must combine data from three different sources: your blood, your bone marrow, and your genes ^[1][2].

Decoding the Technical Language

When you open your report, you will likely encounter several complex terms. Understanding these is the first step to navigating your care:

• Hypercellularity: This means your bone marrow has more blood-forming cells than is normal for your age. In aCML, this is usually because the granulocytic (white blood cell) line is proliferating ^[3][4].
• Dysgranulopoiesis (Granulocytic Dysplasia): This describes white blood cells that developed abnormally. They may have “hyposegmented” nuclei (looking like a single lump instead of several connected segments) or abnormal granules. This is a hallmark feature required for aCML ^[5][6].
• Blasts: These are primitive blood cells. In aCML, these must be less than 20%. If they reach 20%, it is the usual threshold for AML transformation in this setting ^[7][8].
• Karyotype: A map of your chromosomes. It helps doctors rule out other diseases and look for large-scale genetic damage ^[1].
• NGS (Next-Generation Sequencing): A test that looks for tiny mutations in your DNA, such as SETBP1, ASXL1, or ETNK1 ^[5][9]. A negative NGS panel does not rule out the disease, and no particular mutation is required.
• Cytopenia: A lower-than-normal level of a specific blood cell (like red cells or platelets). The ICC classification requires at least one cytopenia for a formal aCML diagnosis ^[3].

The ‘Completeness Checklist’

Because aCML is rare and complex, reports can sometimes be incomplete. Use this checklist as a guide to what your medical team will look for in your record:

1. [ ] Total White Blood Cell Count: Is it ≥13,000 per microliter? ^[3]
2. [ ] Immature Myeloid Cells: Are they ≥10% of the white blood cells? ^[7]
3. [ ] Monocyte Count: Is it documented as <10%? ^[10]
4. [ ] Blast Percentage: Is it clearly stated for both blood and bone marrow, and is it <20%? ^[7]
5. [ ] Exclusions: Is there a confirmed negative result for the BCR::ABL1 fusion, and have other rearrangements (like PDGFRA/B or PCM1-JAK2) been excluded? ^[10]
6. [ ] Marrow Findings: Is there explicit documentation of dysgranulopoiesis, marrow hypercellularity, and granulocytic proliferation? ^[3]
7. [ ] Molecular Panel (NGS): Did they test for supporting mutations to help differentiate the disease? ^[5]
8. [ ] Classification System: Does the report specify if they are using the WHO (MDS/MPN with neutrophilia) or ICC (aCML) criteria, and are cytopenias documented if using ICC? ^[3]

What the Bone Marrow Finding “Looks” Like

On your report, a hypothetical description of the marrow findings compatible with aCML might look like this:

“The marrow is markedly hypercellular (90% cellularity) with a prominent shift toward immature granulocytic forms. Granulocytic dysplasia is noted, including hyposegmented neutrophils and abnormal nuclear contour. Blasts represent 3% of the total marrow cells.”

This description illustrates some compatible findings, showing that the marrow is overproducing (hypercellular) and that the cells it is making are dysplastic, while still remaining below the blast threshold for acute leukemia. However, these findings alone do not confirm a diagnosis without peripheral-blood counts, cytopenia status, monocyte percentage, and BCR::ABL1 testing ^[3][7].

If Your Report is Incomplete

If you notice that key data points are missing, do not panic.

• Ask for an Addendum: Your doctor can request the pathologist to provide additional details or “add-on” tests to the existing samples.
• Request a Second Opinion: Because aCML is ultra-rare, final classification should be made by the treating hematologist and hematopathologist. It is common to have your “slides” (the physical samples) sent to a specialized academic center where experts can review them ^[11].
• Clarify the NGS: Ask if a more comprehensive “myeloid panel” is appropriate, while remembering that molecular testing supports the diagnosis but does not replace clinical review ^[5].